Ataxia telangiectasia

Handbook of Clinical Neurology

Volumn 132, Issue , 2015, Pages 199-214

  Nissenkorn, Andreea ^a,b   Ben Zeev, Bruria ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

ATM; Cerebellar; DNA repair; Movement disorder; Neurodegeneration

Indexed keywords

ATM PROTEIN; ATM PROTEIN, HUMAN;

ATAXIA TELANGIECTASIA; GENETICS; HUMAN; MUTATION; PATHOPHYSIOLOGY;

ATAXIA TELANGIECTASIA; ATAXIA TELANGIECTASIA MUTATED PROTEINS; HUMANS; MUTATION;

EID: 84961240749     PISSN: 00729752     EISSN: 22124152     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62702-5.00014-7     Document Type: Chapter

References (138)

1. Alterman N., Fattal-Valevski A., Moyal L., et al. Ataxia-telangiectasia: mild neurological presentation despite null ATM mutation and severe cellular phenotype. Am J Med Genet A 2007, 143A:1827-1834.
2. Ambrose M., Gatti R.A. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood 2013, 121:4036-4045.
3. Amromin G.D., Boder E., Teplitz R. Ataxia-telangiectasia with a 32 year survival. A clinicopathological report. J Neuropathol Exp Neurol 1979, 38:621-643.
4. Antoccia A., Kobayashi J., Tauchi H., et al. Nijmegen breakage syndrome and functions of the responsible protein, NBS1. Genome Dyn 2006, 1:191-205.
5. Arnold S.E., Lee E.B., Moberg P.J., et al. Olfactory epithelium amyloid-beta and paired helical filament-tau pathology in Alzheimer disease. Ann Neurol 2010, 67:462-469.
6. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
7. Baloh R.W., Yee R.D., Boder E. Eye movements in ataxia-telangiectasia. Neurology 1978, 28:1099-1104.
8. Barlow C., Hirotsune S., Paylor R., et al. ATM-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996, 86:159-171.
9. Barzilai A., Rotman G., Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to oxidative stress. DNA Repair (Amst) 2002, 1:3-25.
10. Bielorai B., Fisher T., Waldman D., et al. Acute lymphoblastic leukemia in early childhood as the presenting sign of ataxia-telangiectasia variant. Pediatr Hematol Oncol 2013, 30:574-582.
11. Biton S., Dar I., Mittelman L., et al. Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells. J Biol Chem 2006, 281:17482-17491.
12. Biton S., Barzilai A., Shiloh Y. The neurological phenotype of ataxia-telangiectasia: solving a persistent puzzle. DNA Repair (Amst) 2008, 7:1028-1038.
13. Boder E. Ataxia-telangiectasia: some historic, clinical and pathologic observations. Birth Defects Orig Artic Ser 1975, 11:255-270.
14. Boder E., Sedgwick R.P. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics 1958, 21:526-554.
15. Boder E., Sedgwick R.P. Ataxia-telangiectasia (clinical and immunological aspects). Psychiatr Neurol Med Psychol Beih 1970, 13-14:8-16.
16. Bostan A.C., Strick P.L. The cerebellum and basal ganglia are interconnected. Neuropsychol Rev 2010, 20:261-270.
17. Bottini A.R., Gatti R.A., Wirenfeldt M., et al. Heterotopic Purkinje cells in ataxia-telangiectasia. Neuropathology 2012, 32:23-29.
18. Bredemeyer A.L., Huang C.Y., Walker L.M., et al. Aberrant V(D)J recombination in ataxia telangiectasia mutated-deficient lymphocytes is dependent on nonhomologous DNA end joining. J Immunol 2008, 181:2620-2625.
19. Buckner R.L. The cerebellum and cognitive function: 25 years of insight from anatomy and neuroimaging. Neuron 2013, 80:807-815.
20. Calderon D.P., Fremont R., Kraenzlin F., et al. The neural substrates of rapid-onset dystonia-parkinsonism. Nat Neurosci 2011, 14:357-365.
21. Carlessi L., Fusar Poli E., De Filippis L., et al. ATM-deficient human neural stem cells as an in vitro model system to study neurodegeneration. DNA Repair (Amst) 2013, 12:605-611.
22. Carlessi L., Fusar Poli E., Delia D. Brain and induced pluripotent stem cell-derived neural stem cells as an in vitro model of neurodegeneration in ataxia-telangiectasia. Exp Biol Med (Maywood) 2013, 238:301-307.
23. Chessa L., Leuzzi V., Plebani A., et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 trial. Orphanet J Rare Dis 2014, 9:5. PubMed PMID: 24405665; PubMed Central PMCID: PMC3904207. 10.1186/1750-1172-9-5.
24. Ching J.K., Luebbert S.H., Collins R.L., et al. Ataxia telangiectasia mutated impacts insulin-like growth factor 1 signalling in skeletal muscle. Exp Physiol 2013, 98:526-535.
25. Chrzanowska K.H., Gregorek H., Dembowska-Baginska B., et al. Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 2012, 7:13.
26. Chun H.H., Gatti R.A. Ataxia-telangiectasia, an evolving phenotype. DNA Repair (Amst) 2004, 3:1187-1196.
27. Ciemins J.J., Horowitz A.L. Abnormal white matter signal in ataxia telangiectasia. AJNR Am J Neuroradiol 2000, 21:1483-1485.
28. Cohen J.M., Cuckow P., Davies E.G. Bladder wall telangiectasis causing life-threatening haematuria in ataxia-telangiectasia: a new observation. Acta Paediatr 2008, 97:667-669.
29. Cosentino C., Grieco D., Costanzo V. ATM activates the pentose phosphate pathway promoting anti-oxidant defence and DNA repair. EMBO J 2011, 30:546-555.
30. Coutinho P., Barbot C. Ataxia with oculomotor apraxia type 1. GeneReviews 1993, University of Washington, Seattle, Seattle WA. R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
31. Crawford T.O. Ataxia telangiectasia. Semin Pediatr Neurol 1998, 5:287-294.
32. Crawford T.O., Mandir A.S., Lefton-Greif M.A., et al. Quantitative neurologic assessment of ataxia-telangiectasia. Neurology 2000, 54:1505-1509.
33. Crawford T.O., Skolasky R.L., Fernandez R., et al. Survival probability in ataxia telangiectasia. Arch Dis Child 2006, 91:610-611.
34. Cremona C.A., Behrens A. ATM signalling and cancer. Oncogene 2014, 33:3351-3360.
35. Cummins G., Jawad T., Taylor M., et al. Myoclonic head jerks and extensor axial dystonia in the variant form of ataxia telangiectasia. Parkinsonism Relat Disord 2013, 19:1173-1174.
36. Dar I., Biton S., Shiloh Y., et al. Analysis of the ataxia telangiectasia mutated-mediated DNA damage response in murine cerebellar neurons. J Neurosci 2006, 26:7767-7774.
37. Demuth I., Frappart P.O., Hildebrand G., et al. An inducible null mutant murine model of Nijmegen breakage syndrome proves the essential function of NBS1 in chromosomal stability and cell viability. Hum Mol Genet 2004, 13:2385-2397.
38. Ditch S., Paull T.T. The ATM protein kinase and cellular redox signaling: beyond the DNA damage response. Trends Biochem Sci 2012, 37:15-22.
39. Driessen G.J., Ijspeert H., Weemaes C.M., et al. Antibody deficiency in patients with ataxia telangiectasia is caused by disturbed B- and T-cell homeostasis and reduced immune repertoire diversity. J Allergy Clin Immunol 2013, 131:1367-1375 e9.
40. Du L., Jung M.E., Damoiseaux R., et al. A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Mol Ther 2013, 21:1653-1660.
41. Farina L., Uggetti C., Ottolini A., et al. Ataxia-telangiectasia: MR and CT findings. J Comput Assist Tomogr 1994, 18:724-727.
42. Farr A.K., Shalev B., Crawford T.O., et al. Ocular manifestations of ataxia-telangiectasia. Am J Ophthalmol 2002, 134:891-896.
43. Gapud E.J., Sleckman B.P. Unique and redundant functions of ATM and DNA-PKcs during V(D)J recombination. Cell Cycle 2011, 10:1928-1935.
44. Gatti R. Ataxia-t6elangiectasia. GeneReviews 1993, University of Washington, Seattle, Seattle WA. R.A. Pagon, M.P. Adam, T.D. Bird (Eds.).
45. Gatti R.A., Vinters H.V. Cerebellar pathology in ataxia-telangiectasia: the significance of basket cells. Kroc Found Ser 1985, 19:225-232.
46. Gilad S., Bar-Shira A., Harnik R., et al. Ataxia-telangiectasia: founder effect among North African Jews. Hum Mol Genet 1996, 5:2033-2037.
47. Gilad S., Khosravi R., Shkedy D., et al. Predominance of null mutations in ataxia-telangiectasia. Hum Mol Genet 1996, 5:433-439.
48. Greenberger S., Berkun Y., Ben-Zeev B., et al. Dermatologic manifestations of ataxia-telangiectasia syndrome. J Am Acad Dermatol 2013, 68:932-936.
49. Guerra-Maranhao M.C., Costa-Carvalho B.T., Nudelman V., et al. Response to polysaccharide antigens in patients with ataxia-telangiectasia. J Pediatr (Rio J) 2006, 82:132-136.
50. Guo Z., Kozlov S., Lavin M.F., et al. ATM activation by oxidative stress. Science 2010, 330:517-521.
51. Herrup K. ATM and the epigenetics of the neuronal genome. Mech Ageing Dev 2013, 134:434-439.
52. Herrup K., Li J., Chen J. The role of ATM and DNA damage in neurons: upstream and downstream connections. DNA Repair (Amst) 2013, 12:600-604.
53. Hiel J.A., Van Engelen B.G., Weemaes C.M., et al. Distal spinal muscular atrophy as a major feature in adult-onset ataxia telangiectasia. Neurology 2006, 67:346-349.
54. Iyama T., Wilson D.M. DNA repair mechanisms in dividing and non-dividing cells. DNA Repair (Amst) 2013, 12:620-636.
55. Kamsler A., Daily D., Hochman A., et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from Atm-deficient mice. Cancer Res 2001, 61:1849-1854.
56. Kim T.S., Kawaguchi M., Suzuki M., et al. The ZFHX3 (ATBF1) transcription factor induces PDGFRB, which activates ATM in the cytoplasm to protect cerebellar neurons from oxidative stress. Dis Model Mech 2010, 3:752-762.
57. Koziol L.F., Budding D., Andreasen N., et al. Consensus paper: the cerebellum's role in movement and cognition. Cerebellum 2014, 13:151-177.
58. Lantelme E., Turinetto V., Mantovani S., et al. Analysis of secondary V(D)J rearrangements in mature, peripheral T cells of ataxia-telangiectasia heterozygotes. Lab Invest 2003, 83:1467-1475.
59. Lavin M.F. The appropriateness of the mouse model for ataxia-telangiectasia: neurological defects but no neurodegeneration. DNA Repair (Amst) 2013, 12:612-619.
60. Lefton-Greif M.A., Crawford T.O., Winkelstein J.A., et al. Oropharyngeal dysphagia and aspiration in patients with ataxia-telangiectasia. J Pediatr 2000, 136:225-231.
61. Lefton-Greif M.A., Crawford T.O., McGrath-Morrow S., et al. Safety and caregiver satisfaction with gastrostomy in patients with ataxia telangiectasia. Orphanet J Rare Dis 2011, 6:23.
62. Lewis R.F., Lederman H.M., Crawford T.O. Ocular motor abnormalities in ataxia telangiectasia. Ann Neurol 1999, 46:287-295.
63. Li J., Han Y.R., Plummer M.R., et al. Cytoplasmic ATM in neurons modulates synaptic function. Curr Biol 2009, 19:2091-2096.
64. Li J., Chen J., Vinters H.V., et al. Stable brain ATM message and residual kinase-active ATM protein in ataxia-telangiectasia. J Neurosci 2011, 31:7568-7577.
65. Li J., Chen J., Ricupero C.L., et al. Nuclear accumulation of HDAC4 in ATM deficiency promotes neurodegeneration in ataxia telangiectasia. Nat Med 2012, 18:783-790.
66. Lin D.D., Crawford T.O., Lederman H.M., et al. Proton MR spectroscopic imaging in ataxia-telangiectasia. Neuropediatrics 2006, 37:241-246.
67. Lin D.D., Barker P.B., Lederman H.M., et al. Cerebral abnormalities in adults with ataxia-telangiectasia. AJNR Am J Neuroradiol 2014, 35:119-123.
68. Loeb D.M., Lederman H.M., Winkelstein J.A. Lymphoid malignancy as a presenting sign of ataxia-telangiectasia. J Pediatr Hematol Oncol 2000, 22:464-467.
69. Louis-Bar D. Sur un syndrome progressif cormprenant des télangiectasies capillaires cutanées et conjonctivales symétriques, à disposition naevoïde et des troubles cérébelleux. Confin Neurol 1941, 4:32-42.
70. Majdzadeh N., Wang L., Morrison B.E., et al. HDAC4 inhibits cell-cycle progression and protects neurons from cell death. Dev Neurobiol 2008, 68:1076-1092.
71. Marmolino D. Friedreich's ataxia: past, present and future. Brain Res Rev 2011, 67:311-330.
72. McConville C.M., Stankovic T., Byrd P.J., et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet 1996, 59:320-330.
73. McFarlin D.E., Strober W., Waldmann T.A. Ataxia-telangiectasia. Medicine (Baltimore) 1972, 51:281-314.
74. McGrath-Morrow S.A., Gower W.A., Rothblum-Oviatt C., et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol 2010, 45:847-859.
75. McGrath-Morrow S.A., Lederman H.M., Aherrera A.D., et al. Pulmonary function in children and young adults with ataxia telangiectasia. Pediatr Pulmonol 2014, 49:84-90.
76. McKinnon P.J. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol 2012, 7:303-321.
77. Menotta M., Biagiotti S., Bianchi M., et al. Dexamethasone partially rescues ataxia telangiectasia-mutated (ATM) deficiency in ataxia telangiectasia by promoting a shortened protein variant retaining kinase activity. J Biol Chem 2012, 287:41352-41363.
78. Meshulam L., Galron R., Kanner S., et al. The role of the neuro-astro-vascular unit in the etiology of ataxia telangiectasia. Front Pharmacol 2012, 3:157.
79. Micol R., Ben Slama L., Suarez F., et al. Morbidity and mortality from ataxia-telangiectasia are associated with ATM genotype. J Allergy Clin Immunol 2011, 128:382-389 e1.
80. Mitra A., Gooi J., Darling J., Newton-Bishop J.A. Infliximab in the treatment of a child with cutaneous granulomas associated with ataxia telangiectasia. J Am Acad Dermatol 2011, 65:676-677.
81. Mitui M., Nahas S.A., Du L.T., et al. Functional and computational assessment of missense variants in the ataxia-telangiectasia mutated (ATM) gene: mutations with increased cancer risk. Hum Mutat 2009, 30:12-21.
82. Moreira M.C., Klur S., Watanabe M., et al. Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nat Genet 2004, 36:225-227.
83. Mostofsky S.H., Kunze J.C., Cutting L.E., et al. Judgment of duration in individuals with ataxia-telangiectasia. Dev Neuropsychol 2000, 17:63-74.
84. Murphy R.C., Berdon W.E., Ruzal-Shapiro C., et al. Malignancies in pediatric patients with ataxia telangiectasia. Pediatr Radiol 1999, 29:225-230.
85. Nahas S.A., Butch A.W., Du L., et al. Rapid flow cytometry-based structural maintenance of chromosomes 1 (SMC1) phosphorylation assay for identification of ataxia-telangiectasia homozygotes and heterozygotes. Clin Chem 2009, 55:463-472.
86. Nakamura K., Du L., Tunuguntla R., et al. Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia. Hum Mutat 2012, 33:198-208.
87. Nemeth A.H., Kwasniewska A.C., Lise S., et al. Next generation sequencing for molecular diagnosis of neurological disorders using ataxias as a model. Brain 2013, 136:3106-3118.
88. Nissenkorn A., Levi Y.B., Vilozni D., et al. Neurologic presentation in children with ataxia-telangiectasia: is small head circumference a hallmark of the disease?. J Pediatr 2011, 159:466-471 e1.
89. Nissenkorn A., Hassin-Baer S., Lerman S.F., et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol 2013, 28:155-160.
90. Nowak-Wegrzyn A., Crawford T.O., Winkelstein J.A., et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr 2004, 144:505-511.
91. O'Driscoll M., Jeggo P.A. The role of the DNA damage response pathways in brain development and microcephaly: insight from human disorders. DNA Repair (Amst) 2008, 7:1039-1050.
92. Olsen J.H., Hahnemann J.M., Borresen-Dale A.L., et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer Inst 2001, 93:121-127.
93. Ortonne J.P., Claudy A.L., Freycon F. Cafe au lait spots in ataxia-telangiectasia (AT). Histochemical and ultrastructural study in one case. Arch Dermatol Res 1980, 268:91-99.
94. Paller A.S., Massey R.B., Curtis M.A., et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr 1991, 119:917-922.
95. Paula-Barbosa M.M., Ruela C., Tavares M.A., et al. Cerebellar cortex ultrastructure in ataxia-telangiectasia. Ann Neurol 1983, 13:297-302.
96. Perlman S., Becker-Catania S., Gatti R.A. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol 2003, 10:173-182.
97. Petersen A.J., Rimkus S.A., Wassarman D.A. ATM kinase inhibition in glial cells activates the innate immune response and causes neurodegeneration in Drosophila. Proc Natl Acad Sci U S A 2012, 109:E656-E664.
98. Petersen A.J., Katzenberger R.J., Wassarman D.A. The innate immune response transcription factor relish is necessary for neurodegeneration in a Drosophila model of ataxia-telangiectasia. Genetics 2013, 194:133-142.
99. Raz-Prag D., Galron R., Segev-Amzaleg N., et al. A role for vascular deficiency in retinal pathology in a mouse model of ataxia-telangiectasia. Am J Pathol 2011, 179:1533-1541.
100. Reliene R., Schiestl R.H. Experimental antioxidant therapy in ataxia telangiectasia. Clin Med Oncol 2008, 2:431-436.
101. Riise R., Ygge J., Lindman C., et al. Ocular findings in Norwegian patients with ataxia-telangiectasia: a 5 year prospective cohort study. Acta Ophthalmol Scand 2007, 85:557-562.
102. Ronnett G.V., Leopold D., Cai X., et al. Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol 2003, 54:206-218.
103. Sandlund J.T., Hudson M.M., Kennedy W., et al. Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood Cancer 2014, 61:360-362.
104. Sardanelli F., Parodi R.C., Ottonello C., et al. Cranial MRI in ataxia-telangiectasia. Neuroradiology 1995, 37:77-82.
105. Savitsky K., Bar-Shira A., Gilad S., et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995, 268:1749-1753.
106. Schneider J.G., Finck B.N., Ren J., et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab 2006, 4:377-389.
107. Schroeder S.A., Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulmonol 2014, 49:389-399.
108. Schubert R., Reichenbach J., Zielen S. Growth factor deficiency in patients with ataxia telangiectasia. Clin Exp Immunol 2005, 140:517-519.
109. Shaikh A.G., Marti S., Tarnutzer A.A., et al. Gaze fixation deficits and their implication in ataxia-telangiectasia. J Neurol Neurosurg Psychiatry 2009, 80:858-864.
110. Shaikh A.G., Marti S., Tarnutzer A.A., et al. Ataxia telangiectasia: a "disease model" to understand the cerebellar control of vestibular reflexes. J Neurophysiol 2011, 105:3034-3041.
111. Shaikh A.G., Marti S., Tarnutzer A.A., et al. Effects of 4-aminopyridine on nystagmus and vestibulo-ocular reflex in ataxia-telangiectasia. J Neurol 2013, 260:2728-2735.
112. Shaikh A.G., Zee D.S., Mandir A.S., et al. Disorders of upper limb movements in ataxia-telangiectasia. PLoS One 2013, 8:e67042.
113. Shen C., Houghton P.J. The mTOR pathway negatively controls ATM by up-regulating miRNAs. Proc Natl Acad Sci U S A 2013, 110:11869-11874.
114. Shiloh Y., Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol 2013, 14:197-210.
115. Song C.H., Bernhard D., Hess E.J., et al. Subtle microstructural defects of the cerebellum in a knock-in mouse model of DYT1 dystonia. Neurobiol Dis 2014, 62:372-380.
116. Stell R., Bronstein A.M., Plant G.T., et al. Ataxia telangiectasia: a reappraisal of the ocular motor features and their value in the diagnosis of atypical cases. Mov Disord 1989, 4:320-329.
117. Stewart G.S., Maser R.S., Stankovic T., et al. The DNA double-strand break repair gene hMRE11 is mutated in individuals with an ataxia-telangiectasia-like disorder. Cell 1999, 99:577-587.
118. Stewart G.S., Last J.I., Stankovic T., et al. Residual ataxia telangiectasia mutated protein function in cells from ataxia telangiectasia patients, with 5762ins137 and 7271 T->G mutations, showing a less severe phenotype. J Biol Chem 2001, 276:30133-30141.
119. Syllaba L., Henner K. Contribution à l'étude de l'indépendance de l'athétose double idiopathique et congénitale. Atteinte familiale, syndrome dystrophique, signe du résau vasculaire conjonctival, intégrité psychique. Rev Neurol (Paris) 1926, 1:541-560.
120. Takahashi K., Yamanaka S. Induced pluripotent stem cells in medicine and biology. Development 2013, 140:2457-2461.
121. Takahashi K., Okita K., Nakagawa M., et al. Induction of pluripotent stem cells from fibroblast cultures. Nat Protoc 2007, 2:3081-3089.
122. Takahashi T., Tada M., Igarashi S., et al. Aprataxin, causative gene product for EAOH/AOA1, repairs DNA single-strand breaks with damaged 3'-phosphate and 3'-phosphoglycolate ends. Nucleic Acids Res 2007, 35:3797-3809.
123. Tavani F., Zimmerman R.A., Berry G.T., et al. Ataxia-telangiectasia: the pattern of cerebellar atrophy on MRI. Neuroradiology 2003, 45:315-319.
124. Taylor A.M., Byrd P.J. Molecular pathology of ataxia telangiectasia. J Clin Pathol 2005, 58:1009-1015.
125. Taylor A.M., Groom A., Byrd P.J. Ataxia-telangiectasia-like disorder (ATLD)-its clinical presentation and molecular basis. DNA Repair (Amst) 2004, 3:1219-1225.
126. Valentin-Vega Y.A., Kastan M.B. A new role for ATM: regulating mitochondrial function and mitophagy. Autophagy 2012, 8:840-841.
127. Valentin-Vega Y.A., Maclean K.H., Tait-Mulder J., et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood 2012, 119:1490-1500.
128. Van Overwalle F., Baetens K., Marien P., et al. Social cognition and the cerebellum: a meta-analysis of over 350 fMRI studies. Neuroimage 2014, 86:554-572.
129. Verhagen M.M., Last J.I., Hogervorst F.B., et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat 2012, 33:561-571.
130. Verhagen M.M., Martin J.J., Van Deuren M., et al. Neuropathology in classical and variant ataxia-telangiectasia. Neuropathology 2012, 32:234-244.
131. Vinck A., Verhagen M.M., Gerven M., et al. Cognitive and speech-language performance in children with ataxia telangiectasia. Dev Neurorehabil 2011, 14:315-322.
132. Vinters H.V., Gatti R.A., Rakic P. Sequence of cellular events in cerebellar ontogeny relevant to expression of neuronal abnormalities in ataxia-telangiectasia. Kroc Found Ser 1985, 19:233-255.
133. Wallis L.I., Griffiths P.D., Ritchie S.J., et al. Proton spectroscopy and imaging at 3 T in ataxia-telangiectasia. AJNR Am J Neuroradiol 2007, 28:79-83.
134. Wilson B.K., Hess E.J. Animal models for dystonia. Mov Disord 2013, 28:982-989.
135. Woods C.G., Taylor A.M. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med 1992, 82:169-179.
136. Worth P.F., Srinivasan V., Smith A., et al. Very mild presentation in adult with classical cellular phenotype of ataxia telangiectasia. Mov Disord 2013, 28:524-528.
137. Zannolli R., Buoni S., Betti G., et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Mov Disord 2012, 27:1312-1316.
138. Zeviani M., Simonati A., Bindoff L.A. Ataxia in mitochondrial disorders. Handb Clin Neurol 2012, 103:359-372.